The marriage of cytology and cytogenetics

Our plain-English summary of The marriage of cytology and cytogenetics, by P. Dal Cin, X. Qian, E.S. Cibas (Cancer Cytopathology, 2013).

The study

• Authors: P. Dal Cin, X. Qian, E.S. Cibas
• Journal: Cancer Cytopathology
• Published: 2013;121(6):279-90
• Cited by: 15 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

The past 20 years have witnessed extraordinary advances in the field of cytogenetics, with the discovery that a multitude of neoplasms is characterized by identifiable chromosomal changes. The ability of Cytogenetics to aid in the identification and precise classification of a variety of neoplasms has not gone unnoticed by Cytology. In particular, Cytology has recognized Cytogenetics as a welcome companion in the evaluation of soft tissue tumors, lymphomas, renal and urothelial tumors, and mesothelioma. This relationship requires a good understanding of the proper handling of specimens for optimal evaluation by Cytogenetics. The marriage of Cytology and Cytogenetics will likely grow stronger as more solid tumors (eg, salivary gland neoplasms) are discovered that harbor characteristic chromosomal abnormalities.

Copyright © 2013 American Cancer Society.

In plain English

This article was a commentary, not a study of patients. The authors described how cytology (looking at cells, for example from fine-needle aspiration or body fluids) and cytogenetics (looking at chromosomes, including with a method called FISH) can be used together to diagnose tumors. The article covered soft tissue tumors, lymphomas, renal tumors, mesothelioma and bladder cancer. For mesothelioma, the authors wrote that telling benign from malignant mesothelial growths can be difficult using cytology alone. They wrote that chromosome analysis of cells from pleural and other body cavity fluids can help, because consistent chromosomal changes are not seen in benign or reactive growths. They also wrote that a chromosome analysis can come back normal or fail when the malignant mesothelial cells do not grow, and that in this situation a FISH test for deletions of 9p21 and 22q can be helpful. One illustrated pleural fluid example showed a malignant mesothelioma cell with a deletion at 9p21. The article did not discuss asbestos. The authors concluded that the connection between the two fields will likely grow stronger as more solid tumors with characteristic chromosome abnormalities are found.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: commentary (narrative overview, no original patient data)
• Who was studied: No patients were studied. The article discussed tumor types: soft tissue tumors, lymphomas, renal tumors, mesothelioma and bladder (urothelial) cancers.
• Main results:
  • The authors wrote that distinguishing benign from malignant mesothelial proliferations can be difficult using cytology alone.
  • The authors wrote that chromosome analysis of cells from pleural and other body cavity fluids can help make this distinction, because consistent chromosomal changes are not observed in benign or reactive mesothelial proliferations.
  • The authors wrote that a normal or unsuccessful karyotype can result when the malignant mesothelial cells do not proliferate, and that in this case a FISH test for deletions of 9p21 and 22q can be helpful.
  • In an illustrated pleural fluid example of malignant mesothelioma, a definitive diagnosis was not possible by cytology alone. A FISH image showed one red 9p21 signal in the malignant cell, which the authors described as a heterozygous deletion.
  • The authors wrote that a normal karyotype does not exclude malignancy.
• The authors' conclusion: The authors concluded that the combined use of cytology and cytogenetics will likely grow as more solid tumors with characteristic chromosomal abnormalities are discovered.

Topics

Medical terms in this study, explained in our Lexicon: Cytology, Discovery, Neoplasm, Mesothelioma.

Related studies

• Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma — A.A. Sandberg, J.A. Bridge (2001)
• Investigating unilateral pleural effusions: the role of cytology — D.T. Arnold, D. De Fonseka, et al. (2018)
• External quality assurance in nongynecologic cytology: The Australasian experience — P.W. Shield, F. Frost, et al. (2017)
• Categorical systems for reporting of cytology specimens: Following the footsteps of Bethesda-like reporting systems — L.J. Layfield, Z. Baloch (2020)
• Ancillary studies in pleural, pericardial, and peritoneal effusion cytology — K.E. Sundling, E.S. Cibas (2018)
• Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology — A. Hjerpe, V. Ascoli, et al. (2015)

Browse more research in Cancer Cytopathology, or return to medical research.